Pharmacogenomics (PGx) Market Trends

ID: MRFR/HC/0671-HCR

200 Pages

Rahul Gotadki

February 2026

Pharmacogenomics Market Research Report: Size, Share, Trend Analysis By Applications (Oncology, Cardiology, Neurology, Infectious Diseases, psychiatry), By Test Type (Genetic Tests, Molecular Tests, Biomarker Tests, Next-Generation Sequencing Tests), By End Users (Pharmaceutical Companies, Diagnostic Laboratories, Research Organizations, Healthcare Providers), By Technology (Microarrays, Polymerase Chain Reaction, Mass Spectrometry, Next-Generation Sequencing) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Request Free Sample

Summary Table of Contents Segmentation Download PDF

Market Trends

Key Emerging Trends in the Pharmacogenomics Market

The marketplace trends of pharmacogenomics are witnessing a surge because of the growing demand for personalized medicine. Patients and healthcare vendors are recognizing the cost of tailoring drug remedies based on a man or woman's genetic makeup, main to extra powerful and cantered treatment options. The incidence of continual diseases is on the upward thrust globally, creating an urgent want for more precise and efficient treatment approaches. Pharmacogenomics affords an answer by offering insights into how an affected person's genetic profile might also have an impact on their reaction to medicines, thereby optimizing healing results. The integration of massive facts analytics in pharmacogenomics is shaping marketplace developments. The potential to research giant amounts of genetic facts is critical for figuring out styles, correlations, and predictive markers. This, in flip, complements the understanding of drug-gene interactions and helps the development of focused remedies. The pharmacogenomics landscape is witnessing a growth in collaborations and partnerships among pharmaceutical companies, research institutions, and generation providers. These alliances' purpose is to pool assets, share information, and accelerate the improvement of pharmacogenomic answers, fostering innovation and a market boom. Governments and regulatory bodies are spotting the importance of pharmacogenomics and are imparting help via pointers and policies. This regulatory backing instills self-belief within the enterprise, encourages funding, and ensures that pharmacogenomic products meet stringent first-class and protection standards. There is a growing awareness among healthcare specialists about the advantages of pharmacogenomics. As education and schooling packages on genetic testing and interpretation grow to be more significant, healthcare providers are more ready to incorporate genomic statistics into their selection-making processes, leading to improved effects on affected persons. Cancer pharmacogenomics is rising as a great recognition region within the marketplace. The expertise of genetic mutations and versions influencing cancer susceptibility and treatment reaction is using the improvement of cantered treatments, contributing to the general increase of the pharmacogenomics zone. Patients are becoming more empowered and actively worried about their healthcare selections. Pharmacogenomics empowers patients by supplying insights into how their genetic makeup may influence treatment results. This fashion is fostering a shift towards more personalized and affected person-centric healthcare fashions.

Market Highlights

Author

Rahul Gotadki

Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

FAQs

What is the current valuation of the Pharmacogenomics Market in 2025?

The Pharmacogenomics (PGx) Technology Market is valued at approximately 4.77 USD Billion in 2024.

What is the projected market size for the Pharmacogenomics Market by 2035?

The market is expected to reach a valuation of 10.54 USD Billion by 2035.

. What is the expected CAGR for the Pharmacogenomics Market during the forecast period 2025 - 2035?

The expected CAGR for the Pharmacogenomics Market during the forecast period 2025 - 2035 is 7.47%.

Which application segments are driving growth in the Pharmacogenomics Market?

The Oncology segment is projected to grow from 1.5 USD Billion to 3.3 USD Billion, indicating strong growth potential.

What are the key test types contributing to the Pharmacogenomics Market?

Genetic Tests are anticipated to increase from 1.43 USD Billion to 3.2 USD Billion, showcasing significant demand.

Who are the leading players in the Pharmacogenomics Market?

Key players include Thermo Fisher Scientific, Illumina, Roche, and Myriad Genetics, among others.

What end-user segments are expected to expand in the Market?

Pharmaceutical genomics testing companies are projected to grow from 1.9 USD Billion to 4.2 USD Billion, reflecting robust market dynamics.

Which technologies are pivotal in the Pharmacogenomics Market?

Next-Generation Sequencing is expected to rise from 1.52 USD Billion to 3.24 USD Billion, indicating its critical role.

How does the market for Neurology applications compare to other segments?

The Neurology segment is projected to grow from 0.9 USD Billion to 2.0 USD Billion, suggesting a steady increase.

What is the growth outlook for the Diagnostic Laboratories segment in the Market?

The Diagnostic Laboratories segment is expected to expand from 1.2 USD Billion to 2.6 USD Billion, indicating a positive trend.

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

Market Summary

As per Market Research Future analysis, the Pharmacogenomics Market Size was estimated at 4.77 USD Billion in 2024. The Pharmacogenomics (PGx) Technology industry is projected to grow from 5.126 USD Billion in 2025 to 10.54 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 7.4% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The Pharmacogenomics Market is poised for substantial growth driven by technological advancements and increasing demand for personalized medicine.

The rising adoption of personalized medicine is reshaping treatment paradigms across various healthcare sectors. Technological advancements in genetic testing are enhancing the accuracy and efficiency of pharmacogenomic applications. North America remains the largest market, while Asia-Pacific is emerging as the fastest-growing region in pharmacogenomics. The growing demand for targeted therapies and regulatory support are key drivers propelling market expansion.

Pharmacogenomics Market

CAGR

7.47%

Market Size & Forecast

2024 Market Size	4.77 (USD Billion)
2035 Market Size	10.54 (USD Billion)
CAGR (2025 - 2035)	7.47%
Largest Regional Market Share in 2024	North America

Major Players

Thermo Fisher Scientific (US), Illumina (US), Roche (CH), <a href="https://digitalinsights.qiagen.com/pgxi/">Qiagen</a> (DE), Myriad Genetics (US), Agilent Technologies (US), Abbott Laboratories (US), Genoa Healthcare (US)

Market Trends

The Pharmacogenomics Market is currently experiencing a transformative phase, driven by advancements in genetic research and personalized medicine. This sector focuses on how an individual's genetic makeup influences their response to drugs, thereby enhancing therapeutic efficacy and minimizing adverse effects. As healthcare systems increasingly adopt precision medicine approaches, the demand for pharmacogenomic testing is likely to rise. This trend is further supported by the growing awareness among healthcare professionals and patients regarding the benefits of tailored treatments. Moreover, regulatory bodies are beginning to recognize the importance of Pharmacogenomics Technology in drug development and patient care. This recognition may lead to more streamlined approval processes for pharmacogenomic tests and therapies, fostering innovation within the industry. The integration of pharmacogenomics (PGx) into clinical practice appears to be gaining momentum, suggesting a promising future for the Pharmacogenomics Market as it aligns with the broader shift towards personalized healthcare solutions.

Rising Adoption of Personalized Medicine

The trend towards personalized medicine is gaining traction, as healthcare providers increasingly recognize the value of tailoring treatments based on individual genetic profiles. This shift is likely to enhance patient outcomes and optimize therapeutic strategies.

Technological Advancements in Genetic Testing

Innovations in genetic testing technologies are facilitating more accurate and efficient pharmacogenomic analyses. These advancements may lead to broader accessibility and affordability of testing, thereby expanding the Pharmacogenomics Market.

Increased Collaboration Between Stakeholders

There appears to be a growing collaboration among pharmaceutical genomics testing companies, healthcare providers, and research institutions. This synergy could foster the development of new pharmacogenomic applications and enhance the overall effectiveness of treatments.

Pharmacogenomics Market Market Drivers

Regulatory Support and Initiatives

Regulatory support plays a crucial role in the advancement of the Market. Governments and health authorities are increasingly recognizing the importance of Pharmacogenomics (PGx) in improving healthcare outcomes. Initiatives such as the FDA's guidance on pharmacogenomic biomarkers are fostering an environment conducive to innovation. These regulations encourage pharmaceutical companies to incorporate genetic testing into drug development processes, thereby streamlining the approval of personalized therapies. Furthermore, the establishment of reimbursement policies for Pharmacogenomics Technology tests is likely to enhance accessibility for patients. As a result, the Market is expected to expand, driven by supportive regulatory frameworks that promote the integration of genetic insights into clinical practice.

Growing Demand for Targeted Therapies

The rising demand for targeted therapies is a pivotal driver in the Pharmacogenomics (PGx) Market. As healthcare shifts towards personalized medicine, the need for treatments tailored to individual genetic profiles becomes increasingly apparent. This trend is underscored by the fact that approximately 70% of new drugs are designed to target specific genetic mutations. Consequently, pharmaceutical companies are investing heavily in Pharmacogenomics Technology research to develop therapies that align with patients' genetic makeups. This not only enhances treatment efficacy but also minimizes adverse drug reactions, thereby improving patient outcomes. The Market is likely to witness substantial growth as healthcare providers and patients alike recognize the benefits of these tailored approaches.

Rising Prevalence of Genetic Disorders

The increasing prevalence of genetic disorders is a significant driver of the Pharmacogenomics (PGx) Market. With an estimated 1 in 10 individuals affected by a genetic condition, the demand for effective diagnostic and therapeutic solutions is surging. Pharmacogenomics Technology offers the potential to identify the most effective treatments based on an individual's genetic profile, thereby addressing the unique challenges posed by these disorders. The market for pharmacogenomic testing is projected to grow at a compound annual growth rate of over 10% in the coming years, reflecting the urgent need for personalized approaches in managing genetic diseases. This trend underscores the critical role of Pharmacogenomics (PGx) in enhancing patient care and treatment outcomes.

Advancements in Bioinformatics and Data Analytics

Advancements in bioinformatics and data analytics are transforming the Market. The ability to analyze vast amounts of genetic data has become increasingly sophisticated, enabling researchers to uncover insights that were previously unattainable. This technological evolution facilitates the identification of genetic variants associated with drug response, thereby enhancing the development of personalized therapies. Moreover, the integration of artificial intelligence and machine learning in pharmacogenomic research is likely to accelerate the discovery of novel biomarkers. As a result, the Pharmacogenomics Technology is poised for growth, driven by the continuous evolution of data analytics tools that enhance the understanding of genetic influences on drug efficacy.

Increasing Awareness Among Healthcare Professionals

Increasing awareness among healthcare professionals regarding the benefits of Pharmacogenomics (PGx) is a vital driver in the Market. As medical education incorporates genetic principles into curricula, clinicians are becoming more adept at utilizing pharmacogenomic information in their practice. This heightened awareness is leading to more informed prescribing practices, ultimately improving patient outcomes. Surveys indicate that over 60% of healthcare providers believe pharmacogenomic testing can enhance treatment decisions. Consequently, the demand for pharmacogenomic services is likely to rise, as healthcare professionals seek to leverage genetic insights to optimize therapy. This trend is expected to propel the Market forward, as the integration of Pharmacogenomics (PGx) into routine clinical practice becomes more prevalent.

Market Segment Insights

By Application: Oncology (Largest) vs. Cardiology (Fastest-Growing)

In the Pharmacogenomics Technology, Oncology stands out as the largest application segment, significantly dominating market share due to its critical role in personalized treatment strategies. Its focus on tailoring cancer therapies based on genetic profiles has made it a primary area of development for pharmaceutical genomics testing companies, researchers, and healthcare providers alike. Cardiology follows closely, showing a rising trend as pharmacogenomic testing becomes integral in managing heart diseases, optimizing drug selections, and mitigating adverse effects related to cardiovascular medications.

Oncology (Dominant) vs. Cardiology (Emerging)

The Oncology application in holds a dominant position as it drives innovations in personalized medicine, focusing on specific genetic markers to optimize treatment plans. Its extensive research output and integration into clinical practices position Oncology as a key player in the precision medicine landscape. Conversely, the Cardiology segment represents an emerging frontier, with increasing recognition of the need for personalized approaches to cardiovascular treatment. Advancements in genetic testing capabilities are enabling more targeted therapies, thereby transforming the management strategies for heart-related conditions and enhancing patient outcomes through tailored interventions.

By Test Type: Genetic Tests (Largest) vs. Next-Generation Sequencing Tests (Fastest-Growing)

In the Pharmacogenomics Market, test types exhibit a diverse distribution of market share. Genetic tests represent the largest share, driven by their extensive use in clinical settings for personalized medicine. In contrast, molecular tests and biomarker tests continue to maintain significant portions of the Pharmacogenomics Market, stemming from their critical role in the precision medicine paradigm. Next-generation sequencing tests, while currently smaller, are rapidly increasing due to advancements in technology and applications in various therapeutic areas. The growth trends in this segment are driven by an increasing demand for personalized treatment options and advancements in genomic technologies. The adoption of next-generation sequencing tests is particularly noteworthy, as they are becoming the preferred choice for comprehensive genomic profiling. Additionally, regulatory support and a rising awareness among healthcare providers regarding the benefits of Pharmacogenomics (PGx) are fueling the segment's expansion, paving the way for innovative solutions and improved patient outcomes.

Genetic Tests (Dominant) vs. Biomarker Tests (Emerging)

Genetic tests hold a dominant position in the market, primarily utilized to identify genetic variations that influence drug response. Their established application in clinical practice makes them indispensable for personalized medicine strategies. On the other hand, biomarker tests are emerging as significant contributors to the Pharmacogenomics Market. They facilitate the identification of specific biological markers that predict therapeutic responses, offering valuable insights for targeted therapies. While genetic tests continue to lead in adoption, the growing recognition of biomarkers' role in precision medicine highlights an exciting shift. Emerging technologies and increased investment in research are expected to further boost the development and utility of biomarker tests in the near future.

By End User: Pharmaceutical Companies (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

The Pharmacogenomics Market is significantly influenced by its end-user segments, primarily dominated by Pharmaceutical Companies, which account for a substantial share. This segment benefits from the integration of genomic data in drug development, enabling personalized medicine approaches. Diagnostic Laboratories follow closely, leveraging advanced technologies to perform personalized testing, thus capturing a noteworthy portion of the Pharmacogenomics Market share. Research Organizations and Healthcare Providers also contribute but to a lesser extent, focusing more on the exploratory and application aspects of Pharmacogenomics (PGx) respectively.

Pharmaceutical Companies (Dominant) vs. Diagnostic Laboratories (Emerging)

Pharmaceutical Companies are the dominant players in the market due to their critical role in drug discovery and development. They utilize genetic information to create targeted therapies, enhancing treatment efficacy and minimizing adverse effects. In contrast, Diagnostic Laboratories are emerging as key contributors in this market by providing genomic testing services that facilitate personalized healthcare solutions. Their growth is driven by advancements in sequencing technologies and an increasing focus on precision medicine. As healthcare shifts towards tailored treatments, both segments are expected to play pivotal roles, with pharmaceutical companies leading and diagnostic laboratories rapidly adapting to new scientific developments.

By Technology: Next-Generation Sequencing (Largest) vs. Mass Spectrometry (Fastest-Growing)

In the Pharmacogenomics Market, Next-Generation Sequencing (NGS) holds the largest market share, attributed to its ability to quickly analyze vast amounts of genetic data. Technologies like Microarrays and Polymerase Chain Reaction follow but have seen relatively restricted growth compared to the promising advances in NGS. Mass Spectrometry also demonstrates a significant presence, particularly in newer applications and advancements in drug response assessments.

Technology: Microarrays (Dominant) vs. Polymerase Chain Reaction (Emerging)

Microarrays are a well-established technology in the Market, widely used for their capability to analyze multiple genes simultaneously, thus offering comprehensive insights into patient drug responses. In contrast, the Polymerase Chain Reaction (PCR) technology is emerging as a complementary tool, especially for its precision in amplifying specific DNA sequences. While Microarrays maintain a dominant position due to established applications in diagnostics, PCR is gaining momentum due to innovations that enhance its applicability in personalized medicine and targeted therapies.

Get more detailed insights about Pharmacogenomics (PGx) Market Research Report – Forecast Till 2035

Regional Insights

North America : Leading Innovation and Research

North America is the largest market for pharmacogenomics, holding approximately 45% of the global share. The region benefits from advanced healthcare infrastructure, significant investment in research and development, and a growing emphasis on personalized medicine. Regulatory support from agencies like the FDA further drives Pharmacogenomics Market growth, as they promote the integration of pharmacogenomic testing in clinical practice. The United States is the primary contributor, with key players such as Thermo Fisher Scientific, Illumina, and Myriad Genetics leading the charge. Canada also plays a significant role, focusing on integrating Pharmacogenomics (PGx) into healthcare systems. The competitive landscape is characterized by continuous innovation and collaboration among industry leaders, enhancing the overall Pharmacogenomics Market dynamics.

Europe : Emerging Market with Potential

Europe is witnessing a rapid increase in the adoption of pharmacogenomics, holding around 30% of the global market share. The region's growth is driven by supportive regulatory frameworks, such as the European Medicines Agency's initiatives to promote personalized medicine. Countries like Germany and the UK are at the forefront, emphasizing the importance of genetic testing in treatment protocols. Germany leads the Pharmacogenomics Market, followed closely by the UK and France, with a strong presence of the best pharmacogenetic testing companies like Roche and Qiagen. The competitive landscape is evolving, with increasing collaborations between academic institutions and industry players to enhance research and development. This synergy is expected to propel the Pharmacogenomics Market further, making Europe a key player in the Pharmacogenomics (PGx) sector.

Asia-Pacific : Rapid Growth and Investment

Asia-Pacific is rapidly emerging as a significant player in the market, accounting for approximately 20% of the global share. The region's growth is fueled by increasing healthcare expenditure, rising awareness of personalized medicine, and government initiatives to promote genetic research. Countries like China and Japan are leading this growth, supported by favorable regulatory environments. China is the largest market in the region, with substantial investments in biotechnology and genomics. Japan follows closely, with a strong focus on integrating Pharmacogenomics (PGx) into healthcare. The competitive landscape features both local and international players, including Agilent Technologies and Abbott Laboratories, driving innovation and expanding market reach.

Middle East and Africa : Untapped Potential and Growth

The Middle East and Africa region is in the early stages of developing its Pharmacogenomics Market, currently holding about 5% of the global share. The growth is driven by increasing healthcare investments, a rising prevalence of chronic diseases, and a growing interest in personalized medicine. Countries like South Africa and the UAE are beginning to adopt pharmacogenomic practices, supported by government initiatives to enhance healthcare quality. South Africa is leading the Pharmacogenomics Market, with efforts to integrate Pharmacogenomics Technology into public health strategies. The competitive landscape is still developing, with opportunities for both local and international companies to establish a presence. As awareness grows, the region is expected to see significant advancements in Pharmacogenomics (PGx), paving the way for future growth.

Key Players and Competitive Insights

The Pharmacogenomics Market is currently characterized by a dynamic competitive landscape, driven by advancements in personalized medicine and the increasing demand for tailored therapeutic solutions. Key pharmacogenomics companies such as Thermo Fisher Scientific (US), Illumina (US), and Roche (CH) are at the forefront, leveraging their technological capabilities and extensive research networks to enhance their market positions. These genomics testing companies are focusing on innovation, strategic partnerships, and regional expansions to capitalize on emerging opportunities, thereby shaping a competitive environment that is both collaborative and competitive.
In terms of business tactics, genomics testing companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The market structure appears moderately fragmented, with several pharmacogenomics companies vying for dominance while also collaborating on various initiatives. This collective influence of key players fosters a competitive atmosphere that encourages innovation and rapid advancements in pharmacogenomic technologies.
In August 2025, Illumina (US) announced a strategic partnership with a leading healthcare provider to integrate its genomic sequencing technologies into routine clinical practice. This collaboration aims to streamline the adoption of pharmacogenomic testing, potentially enhancing patient outcomes through personalized treatment plans. The strategic importance of this partnership lies in its potential to expand Illumina's market reach and solidify its position as a leader in the Pharmacogenomics Technology space.
In September 2025, Roche (CH) unveiled a new pharmacogenomic testing platform designed to improve the accuracy of drug response predictions. This innovative platform is expected to facilitate more precise treatment decisions, thereby enhancing patient care. The introduction of this technology underscores Roche's commitment to advancing personalized medicine and reflects a broader trend towards integrating advanced diagnostics into therapeutic protocols.
In July 2025, Thermo Fisher Scientific (US) expanded its product portfolio by acquiring a small biotech firm specializing in pharmacogenomic assays. This acquisition is likely to enhance Thermo Fisher's capabilities in developing cutting-edge diagnostic solutions, positioning the company to better meet the growing demand for personalized medicine. Such strategic moves indicate a trend towards consolidation in the market, as genomics testing companies seek to bolster their technological expertise and product offerings.
As of October 2025, current competitive trends in the Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are playing a crucial role in shaping the landscape, enabling genomics testing companies to pool resources and expertise to drive innovation. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on technological innovation, supply chain reliability, and the ability to deliver personalized healthcare solutions.

Key Companies in the Pharmacogenomics Market include

Industry Developments

The Pharmacogenomics Market has recently witnessed significant developments with various best pharmacogenetic testing companies, including Thermo Fisher Scientific and Roche, enhancing their product offerings to cater to personalized medicine. In March 2023, Agilent Technologies launched its latest genomic analysis platform aimed at improving drug response prediction, contributing to the rising demand for pharmacogenomic tests. The Pharmacogenomics Market is also experiencing an uptick in investments, particularly by Illumina and Myriad Genetics, to expand their genetic testing capabilities.

Future Outlook

Pharmacogenomics Market Future Outlook

The Pharmacogenomics Market is projected to grow at a 7.47% CAGR from 2025 to 2035, driven by advancements in personalized medicine, regulatory support, and increasing demand for tailored therapies.

New opportunities lie in:

<p>Development of integrated pharmacogenomic testing platforms for clinical use. Expansion of Pharmacogenomics (PGx) in oncology drug development. Partnerships with healthcare providers for personalized treatment plans.</p>

By 2035, the Pharmacogenomics (PGx) Market is expected to be robust, driven by innovation and strategic collaborations.

Market Segmentation

Pharmacogenomics Technology Market End User Outlook

Pharmaceutical Companies
Diagnostic Laboratories
Research Organizations
Healthcare Providers

Pharmacogenomics Technology Market Test Type Outlook

Genetic Tests
Molecular Tests
Biomarker Tests
Next-Generation Sequencing Tests

Pharmacogenomics Technology Market Technology Outlook

Microarrays
Polymerase Chain Reaction
Mass Spectrometry
Next-Generation Sequencing

Pharmacogenomics Technology Market Application Outlook

Oncology
Cardiology
Neurology
Infectious Diseases
Psychiatry

Report Scope

MARKET SIZE 2024	4.77(USD Billion)
MARKET SIZE 2025	5.126(USD Billion)
MARKET SIZE 2035	10.54(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	7.47% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Thermo Fisher Scientific (US), Illumina (US), Roche (CH), Qiagen (DE), Myriad Genetics (US), Agilent Technologies (US), Abbott Laboratories (US), Genoa Healthcare (US)
Segments Covered	Applications, Test Type, End Users, Technology, Regional
Key Market Opportunities	Integration of artificial intelligence in personalized medicine enhances growth potential in the Pharmacogenomics Market.
Key Market Dynamics	Rising demand for personalized medicine drives innovation and competition in the Pharmacogenomics Technology landscape.
Countries Covered	North America, Europe, APAC, South America, MEA